CCL2 and cancer: Despite the setbacks in development of CCL2/CCR2 in clinical studies, particularly for inflammatory conditions, the detrimental roles of the CCL2/CCR2 axis in cancer setting have increasingly been appreciated so that the CCL2/CCR2 axis remains to be actively targeted as candidates for immunotherapy (28) (Tables 2, 3).